---
schema_version: "secwatch.filing_event.v1"
accession: "0001653477-24-000055"
form_type: "8-K"
ticker: "NGVT"
cik: "0001653477"
company_name: "Ingevity Corp"
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T02:57:40.703099+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ingevity Q1 2024 net loss of $56M, sales down 13%; reiterates full-year guidance

## Summary
- Net sales $340.1M, down 13% YoY; net loss $56.0M ($1.54 diluted EPS loss).
- Adjusted earnings $19.1M, adjusted EPS $0.52; adjusted EBITDA $76.9M (22.6% margin).
- Operating cash flow negative $12.1M, free cash flow negative $28.7M, including $19.8M cash losses on CTO resales.
- Realized $20M cost savings in Q1; targeting $65-75M for full year 2024.
- Full-year 2024 guidance reaffirmed: sales $1.40B-$1.55B, adjusted EBITDA $365M-$390M.

## SEC filing metadata
- accession: 0001653477-24-000055
- form_type: 8-K
- ticker: NGVT
- cik: 0001653477
- company_name: Ingevity Corp
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653477/000165347724000055/0001653477-24-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653477/000165347724000055/ngvt-20240501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001653477-24-000055
- JSON: https://secwatch.observer/filing/0001653477-24-000055.json
- Plain text: https://secwatch.observer/filing/0001653477-24-000055.txt

## Key facts
- Earnings Releases
  Ingevity Corp reported the three months ended March 31, 2024 results: revenue $340.1 million, net income Net loss of $56.0 million and diluted loss per share (EPS) of $1.54; adjusted earnings of $19.1 million and diluted adju. Guidance reaffirmed.
  - Period: the three months ended March 31, 2024
  - Revenue: $340.1 million
  - Net income: Net loss of $56.0 million and diluted loss per share (EPS) of $1.54; adjusted earnings of $19.1 million and diluted adju
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: John E. Nypaver, Jr. 843-740-2002 investors@ingevity.com Ingevity reports first quarter 2024 financial results HIGHLIGHTS : (comparisons versus prior year period) • Net sales of $340.1 million, down 13% primarily as a result of the repositioning of Performance Chemicals • Net loss of $56.0 million and diluted loss per share (EPS) of $1.54; adjusted earnings of $19.1
  evidence_url: https://www.sec.gov/Archives/edgar/data/1653477/000165347724000055/0001653477-24-000055-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.